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Abstract 
Background: In areas with ongoing malaria transmission, strategies to clear parasites from populations can reduce 
infection and transmission. The objective of this paper was to describe a malaria mass testing and treatment (MTAT) 
intervention implemented in six kebeles (villages) in Amhara Region, Ethiopia, at the beginning of the 2014 transmis-
sion season.
Methods: Intervention kebeles were selected based on incidence of passively detected Plasmodium falciparum and 
mixed (P. falciparum and P. vivax) malaria cases during the 2013 malaria transmission season. All households in inter-
vention kebeles were targeted; consenting residents received a rapid diagnostic test (RDT) and RDT-positive individu-
als received artemether-lumefantrine for P. falciparum/mixed infections or chloroquine for P. vivax. Data were collected 
on MTAT participation, sociodemographic characteristics, malaria risk factors, and RDT positivity.
Results: Of 9162 households targeted, 7974 (87.0 %) participated in the MTAT. Among the 35,389 residents of these 
households, 30,712 (86.8 %) received an RDT. RDT-positivity was 1.4 % (0.3 % P. vivax, 0.7 % P. falciparum, 0.3 % mixed), 
ranging from 0.3 to 5.1 % by kebele; 39.4 % of RDT-positive individuals were febrile, 28.5 % resided in the same house-
hold with another RDT-positive individual, 23.0 % were not protected by vector control interventions [mosquito net or 
indoor residual spray (IRS)], and 7.1 % had travel history. For individuals under 10 years of age, the odds of being RDT-
positive was significantly higher for those with fever, recent use of anti-malarial drugs or residing in the same house-
hold with another RDT-positive individual; 59.0 % of RDT-positive individuals had at least one of these risk factors. For 
individuals 10 years of age and older, the odds of being RDT positive was significantly higher for those with reported 
travel, fever, recent use of anti-malarial drugs, no use of vector control, and those residing in the same household as 
another RDT-positive individual; 71.2 % of RDT-positive individuals had at least one of these risk factors.
Conclusions: In the Ethiopia setting, an MTAT intervention is operationally feasible and can be conducted with high 
coverage. RDT-positivity is low and varies widely by kebele. While several risk factors are significantly associated with 
RDT-positivity, there are still many RDT-positive individuals who do not have any of these risk factors. Strategies that 
target populations for testing and treatment based on these risk factors alone are likely to leave many infections 
undetected.
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Background
More than 63 million people live in areas at risk of 
malaria in Ethiopia and more than  3 million presumed 
and confirmed cases of malaria were reported in 2013 
[1]. Amhara National Regional State is the second-most 
populous region in Ethiopia and accounts for 31  % of 
the national malaria burden [2]. Malaria parasite preva-
lence in this region was estimated at 2 % in 2011 [3] and 
malaria accounted for 22 % of outpatient visits, 24 % of 
hospital admissions, and 10 % of health facility deaths in 
2012 [4]. While the proportion of outpatient visits, hos-
pital admissions and health facility deaths attributed to 
malaria has fallen to 7, 2 and 1 %, respectively, since 2012, 
malaria remains an important source of morbidity and 
mortality in the region [5, 6].
The Ethiopian Federal Ministry of Health is striving to 
achieve substantial progress toward malaria elimination 
in low transmission areas by 2020 [7]. Current malaria 
control strategies in Ethiopia include long-lasting insec-
ticide-treated bed nets (LLINs), indoor residual spray-
ing (IRS), case management and epidemic detection and 
response where appropriate [8]. To move toward malaria 
elimination, new strategies will need to be employed to 
address the large proportion of infections that remain 
asymptomatic or minimally symptomatic and never pre-
sent for testing and treatment [9, 10].
Population-wide or mass approaches that target 
infected individuals for treatment with anti-malarial 
drugs regardless of whether they are symptomatic or pre-
sent-to-care are a means to clear malaria parasites and 
reduce malaria transmission in this context [11]. Mass 
testing and treatment (MTAT) is the testing of an entire 
population with a point-of-care test and administration 
of treatment to individuals with a positive test result. 
Currently, rapid diagnostic tests (RDTs) are the only 
programme-relevant option available. In Ethiopia, the 
current first-line anti-malarial drug for Plasmodium fal-
ciparum and mixed (P. falciparum and P. vivax) malaria 
is artemether-lumefantrine with a regimen of six doses 
over 3  days, with multiple pills in each dose depending 
on weight or age [8]. Adherence to a six-dose regimen 
of artemether-lumefantrine has been found to be low in 
some settings [12, 13]. Given this context, MTAT with 
artemether-lumefantrine and RDTs, with attention to 
treatment adherence, might be a reasonable approach for 
parasite clearance in Ethiopia.
Published literature has reported on MTAT approaches 
to malaria parasite clearance in Burkina Faso, Zambia 
and Zanzibar [14–16], but no literature has described 
the implementation of a mass approach to clear malaria 
parasites from populations in Ethiopia. An MTAT cam-
paign to clear malaria parasites from the population in 
low transmission areas in Amhara Region was conducted 
to evaluate its feasibility, impact and costs to inform the 
Government of Ethiopia’s strategy for malaria elimina-
tion. This paper presents the results of the operational 
feasibility and describes the profile of the targeted popu-
lation and the risk factors associated with RDT-positivity.
Methods
Study sites
Six kebeles (villages) were purposively selected from 
a sample of 209 kebeles in eight districts in Amhara 
Region, Ethiopia, that collectively span the diverse eco-
logical-epidemiological context across the region. Each 
of these kebeles is served by a health post. Health posts 
are primarily located in rural areas, typically staffed by 
two health extension workers (HEWs) employed by the 
Federal Ministry of Health, and serve the surrounding 
kebele with an approximate average population of 5000 
people. Low transmission of both P. falciparum and P. 
vivax occur in the area. At the health posts in these 209 
kebeles, community-based surveillance assistants work 
closely with HEWs, using mobile phones to upload infor-
mation about malaria morbidity and commodities to the 
web-based District Health Information Software (DHIS 
2) health information management system on a weekly 
basis.
Information on population, altitude and the number of 
RDT-confirmed P. falciparum and mixed malaria cases 
passively detected during the 2013 malaria transmission 
season, as reported in DHIS 2, was used to stratify kebe-
les. Strata included: (1) no transmission, with no P. falci-
parum or mixed malaria cases per 1000 population per 
week, (2) very low transmission, with >0 and <0.3 cases 
per 1000 population per week, (3) low transmission and 
high altitude, with ≥0.3 and <1 case per 1000 population 
per week and an altitude ≥2000 m, (4) low transmission 
and low altitude, with ≥0.3 and <1 case per 1000 popula-
tion per week and an altitude <2000 m and, (5) moder-
ate transmission, with ≥1 case per 1000 population per 
week.
Two kebeles were purposively selected from each of the 
three higher transmission strata (strata 3–5) based on 
accessibility, population mobility and the quality of the 
malaria morbidity data reported in DHIS 2. The entire 
kebele was targeted to receive the MTAT intervention. 
Sites included two kebeles in Bahir Dar Zuriya District 
(Dehina Sositu and Yeginid Lomi) and one kebele each 
in Mecha District (Berhan Chora), Aneded District 
(Zengoba), Kalu District (Choresa) and Metema Dis-
trict (Kumer Aftit) (Fig. 1). The population of each kebele 
ranged from 3441 to 8768 people; the combined popula-
tion of all six kebeles was 38,530 in 2014 [17].
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Intervention design
One round of MTAT for malaria was conducted in the 
six kebeles at the beginning of the 2014 malaria transmis-
sion season, from late August through early September. 
Prior to the MTAT implementation, kebele community 
leaders and members of the Health Development Army 
conducted sensitization activities to inform the commu-
nity about the objectives of the MTAT intervention. All 
households in the selected kebeles were censused (enu-
merated and geo-referenced). A total of 91 field teams 
of two surveillance assistants each went door to door to 
all households over a three-week period. The number of 
field teams in a given kebele ranged from 9 to 19, depend-
ing on the size and topography of the kebele. Field teams 
were supervised by staff from the district, zonal and 
regional health offices and the primary health care unit 
responsible for each health post.
All households in the selected kebeles were targeted 
with the aim to visit and test with RDTs the entire pop-
ulation older than 6 months of age and to provide anti-
malarial treatment to all individuals testing positive. 
All households were approached by the field teams and 
invited to participate. The purpose of the intervention 
was explained and oral informed consent was obtained 
from all participants (or their parents or guardians if 
younger than 18 years old) prior to enrollment. At each 
household, the field team administered household and 
individual questionnaires and collected information on 
the geographic coordinates of the household (if not pre-
viously censused), the number of household members, 
mosquito net ownership, receipt of IRS in the previous 
12  months, sociodemographic characteristics (age, sex, 
education, occupation) and individual risk factors for 
malaria (travel history, mosquito net usage, reported 
history of fever). Axillary temperature was measured 
using an electronic thermometer and recorded on the 
questionnaire. Reasons for non-participation were 
recorded for individuals who elected not to participate or 
who were not found at home. If any household members 
were absent at the time of the MTAT visit, the field team 
returned to the household up to two more times over 
the following 1 to 3 days to attempt to find the missing 
household members and conduct testing and treatment.
Available consenting household members older than 
6  months of age were then tested with a CareStart™ 
Malaria Ag P. falciparum/P. vivax RDT for malaria. Indi-
viduals testing positive were treated with artemether-
lumefantrine (P. falciparum, mixed) or chloroquine (P. 
vivax) according to national guidelines [8] and the RDT 
result and the anti-malarial treatment were also recorded 
in the questionnaire. Field teams provided instructions 
on how to take the anti-malarial treatment and observed 
the administration of the first dose of treatment.
Individuals with signs of serious illness, febrile indi-
viduals (axillary temperature ≥37.5  °C or reported fever 
in the last 24 h) who received anti-malarials in the previ-
ous 2  weeks and individuals with a positive RDT result 
who had treatment contra-indications were referred to 
the nearest health centre for evaluation and treatment 
according to national guidelines. Contra-indications 
to artemether-lumefantrine included first trimester of 
pregnancy, history of treatment with artemether-lume-
fantrine or oral quinine in the previous 2  weeks, or 
hypersensitivity to artemether and/or lumefantrine. Con-
tra-indications to chloroquine included hypersensitivity 
to chloroquine, history of epilepsy and psoriasis.
Participants with P. falciparum and mixed malaria 
who received artemether-lumefantrine were followed 
up by field teams approximately 3  days after the ini-
tial MTAT visit to collect information in a standardized 
questionnaire on self-reported and observed adherence 
to treatment and the occurrence of adverse events. Any 
individuals with artemether-lumefantrine treatment 
remaining at the time of the follow-up visit were advised 
to complete treatment according to national guidelines.
Data collection and analysis
Data were collected using smart phones equipped with 
questionnaires developed using Open Data Kit (ODK) 
and a custom android application used to navigate to 
households. Completed questionnaires were either 
uploaded directly from smart phones to an ODK Aggre-
gate server and data repository in real time or manually 
downloaded from the smart phones after data collection 
was complete, depending on internet connectivity.
Data were analysed in Stata 13.1 (© StataCorp, College 
Station, TX, USA). Coverage of the MTAT intervention 
was estimated by calculating the proportion of all enumer-
ated households reached in each kebele and the proportion 
Fig. 1 Map of study area. Showing the location of six health posts 
serving the kebeles that received a malaria MTAT intervention in 
Amhara Region, Ethiopia
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of individuals tested in each household reached. Descrip-
tive statistics were used to create a profile of sociodemo-
graphic characteristics, malaria risk factors, RDT-positivity, 
anti-malarial treatment administration, and adherence to 
treatment for individuals participating in the MTAT.
Risk factors for RDT-positivity were assessed using 
multivariate logistic regression. Two models were run 
separately for under 10 years of age and 10 years of age 
and older because the definition of the education and 
occupation variables differs in children and adults. In 
children it is the mother’s or head of household’s edu-
cation and/or occupation (only the head of household’s 
occupation was available) rather than the individual’s 
education and occupation that are relevant, whereas in 
older children and adults it is pertinent to include the 
individual’s education and occupation. Effect modifica-
tion between age group (under 10 years of age, 10 years 
of age and older) and the individuals’ education and 
occupation were evaluated and a significant interaction 
supported the a priori plan to run the two models sepa-
rately. A univariate analysis was first run to estimate the 
odds ratio (OR) for the association between each variable 
and RDT-positivity. A multivariate model with RDT-pos-
itivity as the dependent variable was then run including 
all variables that had a significant OR in the univariate 
analysis, the kebele and all the a priori confounders/risk 
factors to produce adjusted ORs.
Ethics statement
The study protocol was approved by the Amhara 
National Regional State Health Bureau Research Ethics 
Review Committee and received a non-research determi-
nation from PATH. Oral informed consent was obtained 
from all study participants or their parent or guardian if 
the participant was less than 18 years of age.
Results
Study population and intervention coverage
Among 9162 enumerated households in the six kebe-
les, 7974 (87.0  %) participated in the MTAT interven-
tion (Fig.  2). The majority (80.7  %) of non-participating 
households did not participate because they were never 
visited by a field team during the MTAT; the remaining 
households were visited by a field team but either refused 
to participate in the MTAT (3.8 %) or had no household 
members found at home (15.5 %).
There were 35,389 individuals residing in participat-
ing households, of which 30,712 (86.8 %) were tested for 
malaria. Among the 4677 individuals who were not tested 
during the MTAT, the majority (84.4 %) were not present 
in the household at the time of the MTAT; 6.5 % refused 
to participate, 8.5 % were younger than 6 months of age, 
and 0.6 % did not participate for an unknown reason.
The number of individuals tested in each kebele ranged 
from 3001 to 7765 (Table  1). Of the 30,712 individu-
als tested, 29.1 % were <10 years of age and 47.9 % were 
male; 78.1 % were protected by vector control interven-
tions (slept under a mosquito net the previous night or 
resided in a household that received IRS in the previous 
12 months), ranging from 17.8 to 92.3 % by kebele. Only 
5.9 % of individuals were febrile, 1.4 % had a travel his-
tory (spent at least one night away from home in the pre-
vious month), 5.6 % resided in a household with at least 
one individual with a travel history, and 1.0 % resided in a 
household with more than one RDT-positive individual.
Operational considerations
The 7974 participating households were visited by 91 
field teams over 19 days. On average, each field team vis-
ited 8.4 households per day. The average household had 
4.4 individuals. With 87.0  % of households in the inter-
vention areas reached and 86.8  % of individuals in the 
households reached receiving an RDT, the effective cov-
erage of the MTAT intervention was 75.5 %. Among the 
non-participating households, 80.7 % were never visited 
by the field workers, either because they were missed 
by the field teams, they were duplicated in the census, 
or they were visited but the field teams did not fill out a 
questionnaire with the reason for non-participation. The 
age and sex distribution of the individuals not found at 
home at the time of the MTAT was different than that of 
those found at home. The mean age of those absent was 
26.4 years, compared to 22.8 years for those present and 
the percentage of males was 71.3  % and 48.0  % respec-
tively, with 26.1 % of individuals not found at home being 
males between the ages of 15 and 29 years, compared to 
11.9 % of individuals found at home.
RDT‑positivity
Of the 30,712 individuals with test results, 421 (1.4  %) 
were RDT-positive (0.3  % P. vivax, 0.7  % P. falciparum 
and 0.3  % mixed) (Fig.  2). Nearly all RDT-positive indi-
viduals (95.7  %) were treated with either artemether-
lumefantrine or chloroquine.
Factors associated with RDT‑positivity
RDT-positivity for any species (P. falciparum, P. vivax or 
mixed) varied by kebele, ranging from 0.3 to 5.1  %, and 
by other characteristics (Table  1). The RDT-positivity 
was 9.1  % in febrile individuals, 40.0  % in individuals 
who resided in the same household with another RDT-
positive individual, 1.5 % in those not protected by vector 
control, 6.8 % in individuals who had travel history, 2.5 % 
in those who resided in the same household as at least 
one person with travel history and 27.5 % in those who 
had taken anti-malarial drugs in the previous 2  weeks. 
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While RDT-positivity was low in all age groups, it was 
generally higher in males aged 5 to 29 years and females 
aged 6 months to 14 years (Fig. 3).
Factors associated with RDT-positivity for any spe-
cies for individuals under 10 years of age and individuals 
10 years of age and older are described in Tables 2 and 3, 
respectively. Factors associated with RDT-positivity by 
species (P. falciparum, P. vivax and mixed) are described 
in Additional file  1: Tables S1, S2. For individuals under 
10 years of age, febrile individuals, individuals who took 
anti-malarial drugs in the last 2  weeks and individu-
als residing in a household with at least one other RDT-
positive individual were significantly more likely to be 
RDT-positive for any species after adjusting for all other 
factors (Table  2); 59.0  % of RDT-positive individuals 
under 10 years of age had at least one of these risk factors. 
For individuals 10 years of age or older, individuals who 
had a travel history, were febrile, took anti-malarial drugs 
in the previous 2 weeks, or resided in a household with at 
least one other RDT-positive individual were significantly 
more likely to be RDT-positive for any species when 
compared to individuals without these characteristics 
after adjusting for all other factors (Table  3). Sleeping 
under a mosquito net the previous night and residing 
in a household that received IRS in the last 12  months 
was protective against RDT-positivity for any species. 
Of all RDT-positive individuals 10 years of age or older, 
71.2 % had at least one risk factor (did not sleep under a 
mosquito net the previous night and did not reside in a 
household that received IRS in the last 12 months, had a 
travel history, had a fever, took anti-malarial drugs in the 
last 2  weeks, or resided in a household with more than 
one RDT-positive individual).
Adherence to treatment and adverse events
Of the 308 individuals receiving artemether-lumefan-
trine, 253 (82.1  %) received a follow-up visit. Individu-
als were followed up an average of 3.6  days (range 1 to 
11 days) after being tested. At the time of the follow-up 
visit, 224 individuals (88.5  %) reported having taken at 
Total HHs in 6 intervenon kebeles: 9,162
Total populaon: 38,530 
HHs parcipang: 7,974 (87.0%)
Individuals in parcipang HHs: 35,389
HHs not parcipang: 1,188 (13.0%)
0 (0%) HH not found
959 (80.7%) HH not visited
45 (3.8%) HH visited but HH members refused to parcipate
184 (15.5%) HH visited but HH members not found at home
Individuals tested: 30,712 (86.8%)
Individuals not tested: 4,677 (13.2%)
303 (6.5%) Refused
3,949 (84.4%) Not present
396 (8.5%) <6 months of age
29 (0.6%) Reason not known
RDT-posive: 421 (1.4%)
99 (0.3%) Pv alone
222 (0.7%) Pf alone
100 (0.3%) Pf and Pv
RDT-negave: 30,291 (98.6%)
Received anmalarial at HH visit: 403 (95.7%)
308 (76.4%) Artemether-lumefantrine
95 (23.6%) Chloroquine
Did not receive anmalarial at HH visit: 18 (4.3%)
3 (16.7%) Referred, seriously ill
6 (33.3%) Referred, history of anmalarial use & symptomac
3 (16.7%) Referred, contraindicaons to treatment
3 (16.7%) Recent history of anmalarial use & asymptomac
3 (16.7%) Not treated for unknown reason
Fig. 2 Study profile. Schematic of population reached by a malaria MTAT intervention in Amhara Region, Ethiopia. HH: household
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Table 1 Study population characteristics and RDT-positivity
Total population tested with RDT RDT‑positive for Pv alone, Pf alone, or Pf and Pv (mixed)
N Distribution of  
population tested (%)




Individuals tested with RDT 30,712 100.0 421 1.4 100.0
 Geography
  Kebele 1 (Berhan Chora) 7188 23.4 21 0.3 5.0
  Kebele 2 (Choresa) 3605 11.7 9 0.3 2.1
  Kebele 3 (Dehina Sositu) 7765 25.3 61 0.8 14.5
  Kebele 4 (Kumer Aftit) 3001 9.8 152 5.1 36.1
  Kebele 5 (Yeginid Lomi) 5606 18.3 149 2.7 35.4
  Kebele 6 (Zengoba) 3547 11.6 29 0.8 6.9
Sociodemographic characteristics
 Sex
  Female 15,991 52.1 181 1.1 43.0
  Male 14,721 47.9 240 1.6 57.0
 Age (years)
  <5 3694 12.0 58 1.6 13.8
  5–9 5244 17.1 103 2.0 24.5
  10–14 4224 13.8 58 1.4 13.8
  15–19 3323 10.8 44 1.3 10.5
  20–29 5045 16.4 91 1.8 21.6
  30–39 3647 11.9 29 0.8 6.9
  40–49 2404 7.8 22 0.9 5.2
  50–59 1535 5.0 9 0.6 2.1
  ≥60 1596 5.2 7 0.4 1.7
 Occupation
  No occupation 6525 21.3 104 1.6 24.7
  Migrant labourer 164 0.5 8 4.9 1.9
  Farmer 13,254 43.2 143 1.1 34.0
  Student 6816 22.2 111 1.6 26.4
  Housework 3072 10.0 39 1.3 9.3
  Other 881 2.9 16 1.8 3.8
 Education
  None 20,508 66.8 251 1.2 59.6
  Primary school 8303 27.0 133 1.6 31.6
  Secondary school or higher 1901 6.2 37 2.0 8.8
Malaria risk factors
 Vector controla
  No mosquito net or IRS 6703 21.8 97 1.5 23.0
  Mosquito net and no IRS 8179 26.6 161 2.0 38.2
  IRS and no mosquito net 3538 11.5 48 1.4 11.4
  Mosquito net and IRS 12,292 40.0 115 0.9 27.3
 Spent ≥1 night away from home in last month
  No 30,268 98.6 391 1.3 92.9
  Yes 444 1.4 30 6.8 7.1
 Febrileb
  No 28,888 94.1 255 0.9 60.6
  Yes 1824 5.9 166 9.1 39.4
 Took anti-malarial drugs in last 2 weeks
  No 30,672 99.9 410 1.3 97.4
Page 7 of 13Scott et al. Malar J  (2016) 15:305 
least the first treatment dose. Treatment completion 
could only be assessed for the 96 individuals who were 
followed up more than 3 days after administration of the 
first treatment dose (when all treatment doses should 
have already been taken), of which 41 (42.7 %) reported 
having completed all doses of the treatment and 21 
(21.9  %) were observed to have more than one dose of 
treatment remaining in the blister pack at the time of the 
follow-up visit. No individuals who received a follow-up 
visit reported any adverse event after taking any dose of 
artemether-lumefantrine.
Discussion
The Ethiopian Federal Ministry of Health is striving to 
achieve substantial progress toward malaria elimination 
by 2020 [7]. As new malaria parasite clearance strategies 
are being considered to supplement current vector 
control and case management strategies, information 
from the implementation of a mass parasite clearance 
approach can help guide decision-making. This MTAT 
provided the first in-country experience to inform the 
Ministry of Health’s decision-making about mass malaria 
parasite clearance strategies and the findings have several 
implications for malaria elimination planning and pro-
gramme implementation in Ethiopia.
The results show that it is feasible to implement a mass 
malaria parasite clearance intervention in a large geo-
graphic area over a short period of time. However, it is 
also resource intensive and the two-person field teams 
required additional people and training above and beyond 
existing human resources within the health system. The 
coverage of households (percentage of total households 
in the population that participated) and the coverage of 
individuals within households (percentage of individu-
als in visited households that were included) was high 
(87 % for both). The main reason for not including 13 % 
of the households in the area was that households were 
not visited (81 %), with refusals (4 %) and absent house-
holds (15  %) representing a much lower percentage. In 
the households that were visited, the main reason for not 
including 13 % of the members was that they were absent 
(84 %), while the rest were refusals (7 %) and exclusions 
based on age (infants younger than 6 months, 9 %). This 
resulted in an effective coverage of 75.5 % of all individu-
als in the targeted geographic areas, which was lower than 
desired. Thus greater efforts should be made to improve 
both the households’ and individuals’ coverage, that is 
visit every single household in the targeted areas and, for 
households that are visited but have absent members, try 
to track those individuals when they come back. These 
coverage estimates are comparable to published esti-
mates of coverage for MTAT interventions implemented 
Table 1 continued
Total population tested with RDT RDT‑positive for Pv alone, Pf alone, or Pf and Pv (mixed)
N Distribution of  
population tested (%)




  Yes 40 0.1 11 27.5 2.6
 >1 RDT-positive individual in household
  No 30,412 99.0 301 1.0 71.5
  Yes 300 1.0 120 40.0 28.5
 ≥1 individual in household spent ≥ 1 night away from home in the last month
  No 28,986 94.4 378 1.3 89.8
  Yes 1726 5.6 43 2.5 10.2
Pf Plasmodium falciparum; Pv Plasmodium vivax; RDT rapid diagnostic test
a Slept under a mosquito net last night and/or household received IRS in the last 12 months











































Pf and Pv (mixed)
Fig. 3 Prevalence of RDT-positivity. Prevalence of RDT-positivity for P. 
falciparum, P. vivax or P. falciparum and P. vivax (mixed) malaria by age 
and sex
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Table 2 Odds of an RDT-positive result by risk factor for individuals under 10 years of age
N (% of total popula‑
tion <10 years)
RDT‑positive for Pv alone, Pf alone, or Pf and Pv (mixed)







Adjusted OR  
(95 % CI)c
Individuals tested with 
RDT
8938 (100) 161 1.8 100 – –
 Geography
  Kebele 1 (Berhan 
Chora)
2073 (23.2) 2 0.1 1.2 Ref Ref ***
  Kebele 2 (Choresa) 855 (9.6) 3 0.4 1.9 3.65 (0.61–21.86) 1.83 (0.27–12.56)
  Kebele 3 (Dehina 
Sositu)
2625 (29.4) 32 1.2 19.9 12.78 (3.06–53.38) 6.74 (1.55–29.22)
  Kebele 4 (Kumer 
Aftit)
850 (9.5) 37 4.4 23 47.13 (11.33–195.98) 30.00 (6.88–130.81)
  Kebele 5 (Yeginid 
Lomi)
1555 (17.4) 76 4.9 47.2 53.21 (13.05–216.99) 32.04 (7.06–145.43)
  Kebele 6 (Zengoba) 980 (11.0) 11 1.1 6.8 11.75 (2.60–53.14) 8.15 (1.75–39.94)
Sociodemographic characteristics
 Sex
  Female 4433 (49.6) 82 1.9 50.9 Ref Ref
  Male 4505 (50.4) 79 1.8 49.1 0.95 (0.71–1.27) 0.96 (0.68–1.39)
 Age (years)
  <5 3694 (41.3) 58 1.6 36 Ref Ref
  5–9 5244 (58.7) 103 2 64 1.26 (0.98–1.62) 1.34 (0.92–1.96)
 Occupation of household head
  No occupation 214 (2.4) 6 2.8 3.7 Ref Ref
  Migrant labourer 52 (0.6) 1 1.9 0.6 0.68 (0.07–6.97) 1.30 (0.11–15.3)
  Farmer 6730 (75.3) 116 1.7 72.1 0.61 (0.21–1.74) 1.01 (0.35–2.86)
  Student 45 (0.5) 1 2.2 0.6 0.79 (0.06–10.57) 1.92 (0.19–18.90)
  Housework 212 (2.4) 5 2.4 3.1 0.84 (0.20–3.49) 1.27 (0.29–5.53)
  Other or not known 1685 (18.9) 32 1.9 19.9 0.67 (0.28–1.61) 1.29 (0.43–3.82)
Malaria risk factors
 Vector control1
  No mosquito net 
or IRS
1829 (20.5) 35 1.9 21.7 Ref Ref
  Mosquito net and 
no IRS
2382 (26.7) 80 3.4 49.7 1.78 (0.60–5.26) 0.87 (0.50–1.50)
  IRS and no mosquito 
net
1088 (12.2) 13 1.2 8.1 0.62 (0.13–2.91) 1.08 (0.50–2.31)
  Mosquito net and IRS 3639 (40.7) 33 0.9 20.5 0.47 (0.11–1.96) 0.51 (0.28–0.94)
 Spent ≥1 night away from home in last month
  No 8913 (99.7) 159 1.8 98.8 Ref Ref
  Yes 25 (0.3) 2 8 1.2 4.79 (0.71–32.48) 10.16 (1.18–87.58)
 Febrile2
  No 8458 (94.6) 99 1.2 61.5 Ref Ref***
  Yes 480 (5.4) 62 12.9 38.5 12.52 (4.84–32.43) 15.08 (9.91–22.92)
 Took antimalarial drugs in last 2 weeks
  No 8930 (99.9) 157 1.8 97.5 Ref Ref*
  Yes 8 (0.1) 4 50 2.5 55.88 (30.68–101.78) 12.47 (1.34–116.16)
 >1 RDT-positive individual in household
  No 8834 (98.8) 106 1.2 65.8 Ref Ref***
  Yes 104 (1.2) 55 52.9 34.2 92.42 (27.09–315.34) 50.57 (30.23–84.58)
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elsewhere. During an MTAT campaign in Zanzibar with 
two rounds of testing and treatment, 64  % of the popu-
lation was reached during one or both rounds [16]. Dur-
ing an MTAT campaign in Zambia with three rounds of 
testing and treatment, 88 % of the population was reached 
in one or more rounds [15]. It is likely that a higher pro-
portion of the targeted population (both households and 
individuals) would have been reached if multiple MTAT 
rounds had been implemented. While little information 
(age and sex) was collected about the individuals that were 
not reached during the MTAT implementation, these 
individuals differed from individuals who were reached, 
with more adults and a higher proportion of males, who 
are at higher risk of malaria infection. This suggests that 
a mass malaria parasite clearance approach with a door-
to-door campaign may systematically miss important 
segments of the population if no efforts are made to 
reach individuals who are not at home at the time of the 
campaign. Additional mechanisms would be needed to 
increase the coverage, either by increasing the number 
of visits conducted to households with absent individuals 
and/or through strategies that specifically target mobile 
populations upon their return.
Malaria infection prevalence as measured by RDTs was 
low overall (1.4  %) and varied widely by kebele, ranging 
from 0.3 to 5.1 %. However, malaria prevalence was prob-
ably underestimated due to an imperfect RDT sensitivity. 
While RDTs generally have a high sensitivity in clinical 
settings, their detection limit in the field is around 100 
parasites per µl [18]. Evidence indicates that sub-micro-
scopic infections may be common in low prevalence set-
tings and the intervention may have missed a substantial 
proportion of individuals with malaria infection [19]. In a 
recent MTAT campaign in Zanzibar, RDT sensitivity was 
estimated to be only 5.6 % for infections with any parasite 
density and 47.6 % for infections with parasite densities 
greater than 100 parasites per µl [16]. Thus without more 
sensitive point-of-care tests for malaria, a substantial 
proportion of malaria infections may remain undetected 
and untreated when using an MTAT approach for mass 
malaria parasite clearance. Mass drug administration is 
an alternative for clearing infections that would not oth-
erwise be detected.
Several risk factors were associated with significantly 
higher odds of being RDT-positive. However, only 59 % 
to 71  % (in under ten and over 10  years of age respec-
tively) of RDT-positive individuals had at least one of 
those risk factors. While information on the presence of 
these risk factors could be used to target populations at 
highest risk of malaria infection, screening for these risk 
factors would leave many infections undetected. These 
results also confirm that, even in low transmission areas, 
more than half (60.6 %) of RDT-positive individuals were 
asymptomatic. Interventions that are based on fever 
screening will miss many infections in such a setting [20]. 
Further, these results indicate that population movement 
is a driver of malaria transmission for individuals 10 years 
of age or older. An important income source for many 
families in the area is the seasonal agricultural work that 
young males do in other areas of Amhara with higher 
malaria transmission. Most leave for the farming season 
and come back home between September and December 
[21]. Thus the higher RDT-positivity among young adult 
males is probably a reflection of the large percentage of 
individuals in this age group who are returning migrant 
workers. Previous studies in Ethiopia have also found 
travel history to be a risk factor for malaria [22, 23], sug-
gesting the importance of strategies that target migrant 
workers and other mobile populations to prevent the 
importation of malaria into their home communities. 
Also, given that intra-household transmission is a driver 
for individuals of all ages, mosquito net coverage and 
usage and IRS coverage need to be improved.
Across all kebeles, the field teams tested 73 RDT-neg-
ative individuals for every RDT-positive individual iden-
tified. This ratio ranged from 20 to 401 depending on 
Table 2 continued
N (% of total popula‑
tion <10 years)
RDT‑positive for Pv alone, Pf alone, or Pf and Pv (mixed)







Adjusted OR  
(95 % CI)c
 ≥1 individual in household spent ≥ 1 night away from home in the last month
  No 8516 (95.3) 156 1.8 96.9 Ref Ref
  Yes 422 (4.7) 5 1.2 3.1 0.64 (0.39–1.05) 0.50 (0.15–1.72)
CI confidence interval; IRS indoor residual spraying; OR odds ratio; Pf Plasmodium falciparum; Pv Plasmodium vivax; RDT rapid diagnostic test; Ref reference
* p < 0.05, ** p < 0.01, *** p < 0.001 from likelihood ratio test
a Slept under a mosquito net last night and/or household received IRS in the last 12 months
b Measured fever (axillary temperature ≥ 37.5 °C) or history of fever in last 24 h
c Adjusted Odds Ratios for all sociodemographic characteristics and malaria risk factors
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Table 3 Odds of an RDT-positive result by risk factor for individuals 10 years of age and older
N (% of total popula‑
tion ≥ 10 years)
RDT‑positive for Pv alone, Pf alone, or Pf and Pv (mixed)





Unadjusted OR  
(95 % CI)
Adjusted OR  
(95 % CI)c
Individuals tested with 
RDT
21,774 (100.0) 260 1.2 100.0 – –
 Geography
  Kebele 1 (Berhan 
Chora)
5115 (23.5) 19 0.4 7.3 Ref Ref***
  Kebele 2 (Choresa) 2750 (12.6) 6 0.2 2.3 0.59 (0.23–1.47) 0.57 (0.21–1.52)
  Kebele 3 (Dehina 
Sositu)
5140 (23.6) 29 0.6 11.2 1.52 (0.85–2.72) 1.02 (0.54–1.93)
  Kebele 4 (Kumer 
Aftit)
2151 (9.9) 115 5.4 44.2 15.15 (9.30–24.68) 13.33 (7.73–23.01)
  Kebele 5 (Yeginid 
Lomi)
4051 (18.6) 73 1.8 28.1 4.92 (2.97–8.17) 3.04 (1.60–5.77)
  Kebele 6  
(Zengoba)
2567 (11.8) 18 0.7 6.9 1.89 (0.99–3.62) 1.42 (0.71–2.84)
Sociodemographic characteristics
 Sex
  Female 11,558 (53.1) 99 0.9 38.1 Ref Ref*
  Male 10,216 (46.9) 161 1.6 61.9 1.85 (1.41–2.44) 1.42 (1.04–1.93)
 Age (years)
  10–14 4224 (19.4) 58 1.4 22.3 Ref Ref***
  15–19 3323 (15.3) 44 1.3 16.9 0.96 (0.70–1.33) 0.81 (0.51–1.28)
  20–29 5045 (23.2) 91 1.8 35.0 1.32 (0.89–1.97) 1.10 (0.69–1.74)
  30–39 3647 (16.8) 29 0.8 11.2 0.58 (0.42–0.80) 0.39 (0.22–0.72)
  40–49 2404 (11.0) 22 0.9 8.5 0.66 (0.44–0.99) 0.52 (0.28–0.97)
  50–59 1535 (7.1) 9 0.6 3.5 0.42 (0.20–0.90) 0.34 (0.15–0.77)
  ≥60 1596 (7.3) 7 0.4 2.7 0.32 (0.14–0.71) 0.32 (0.13–0.80)
 Occupation
  No occupation 1063 (4.9) 14 1.3 5.4 Ref Ref
  Migrant labourer 156 (0.7) 8 5.1 3.1 4.05 (2.02–8.12) 2.46 (0.84–7.21)
  Farmer 12,484 (57.3) 136 1.1 52.3 0.83 (0.47–1.44) 1.53 (0.81–2.90)
  Student 5103 (23.4) 69 1.4 26.5 1.03 (0.56–1.90) 1.39 (0.67–2.87)
  Housework 2661 (12.2) 30 1.1 11.5 0.85 (0.40–1.81) 1.01 (0.49–2.09)
  Other 307 (1.4) 3 1.0 1.2 0.74 (0.11–4.76) 0.83 (0.21–3.21)
 Education
  None 13,653 (62.7) 141 1.0 54.2 Ref Ref
  Primary school 6666 (30.6) 90 1.4 34.6 1.31 (0.91–1.90) 1.05 (0.71–1.57)
  Secondary school  
or higher
1455 (6.7) 29 2.0 11.2 1.95 (1.07–3.54) 1.09 (0.65–1.84)
Malaria risk factors
 Vector controla
  No mosquito net 
or IRS
4874 (22.4) 62 1.3 23.9 Ref Ref***
  Mosquito net and 
no IRS
5797 (26.6) 81 1.4 31.2 1.10 (0.33–3.67) 0.81 (0.52–1.24)
  IRS and no mos-
quito net
2450 (11.3) 35 1.4 13.5 1.12 (0.29–4.36) 0.70 (0.42–1.19)
  Mosquito net and  
IRS
8653 (39.7) 82 1.0 31.5 0.74 (0.21–2.63) 0.40 (0.26–0.61)
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kebele, suggesting that the efficiency of a mass malaria 
parasite clearance approach varies widely by geography, 
even within areas with consistently low rates of malaria. 
Focal malaria parasite clearance approaches that target 
specific sub-sets of the population based on proximity to 
passively detected malaria cases may be an efficient alter-
native to mass malaria parasite clearance approaches in 
areas with less malaria transmission [11]. The frequency 
of passively detected malaria cases can be used to deter-
mine which areas to target with population-wide versus 
focal approaches. However, as the risk factor analysis 
showed, any focal strategy that selects the sub-population 
to test based on specific characteristics will leave infec-
tions undetected in the population.
Only 52.7 % of RDT-positive individuals were infected 
by P. falciparum alone; 47.3  % had P. vivax or mixed 
malaria. Mass and focal malaria parasite clearance 
approaches that target P. falciparum alone will leave 
many transmissible P. vivax infections untreated. For 
Ethiopia to move to malaria elimination, strategies for 
malaria parasite clearance will require drugs that effec-
tively clear both P. falciparum and P. vivax infections, 
including clearance of the persistent liver stages in P. 
vivax-infected individuals.
With population-wide treatment approaches using 
a multi-day and multi-dose drug, adherence to the full 
course of treatment is important. Low self-reported 
and observed treatment completion rates were found 
among individuals who received the six-dose regimen 
of artemether-lumefantrine and who were followed up 
more than 3 days after administration of their first dose. 
This is consistent with findings from a recent prospective 
observational study in Ethiopia that found only 38.7 % of 
patients to be ‘probably adherent’ to artemether-lume-
fantrine following administration of the drug in a rou-
tine care setting [12]. Additionally, field teams did not 
always directly observe the intake of the first dose as per 
protocol, with only 88.5  % of participants reporting to 
have taken the first dose. Poor adherence to artemether-
lumefantrine will limit the impact of a mass malaria para-
site clearance approach and attention to adherence is 
critical. New drugs are now available that require fewer 
doses (e.g., dihydroartemisinin-piperaquine) and these 
may provide important advantages for population-wide 
malaria clearance efforts.
The study had some limitations. First, the six inter-
vention kebeles were purposively selected to represent 
variation in malaria transmission intensity, altitude, 
accessibility, and population mobility within Amhara 
Region. While results from a mass malaria parasite clear-
ance approach in these kebeles provides insight into 
potential expansion into other parts of Ethiopia, these 
Table 3 continued
N (% of total popula‑
tion ≥ 10 years)
RDT‑positive for Pv alone, Pf alone, or Pf and Pv (mixed)





Unadjusted OR  
(95 % CI)
Adjusted OR  
(95 % CI)c
 Spent ≥1 night away from home in last month
  No 21,355 (98.1) 232 1.1 89.2 Ref Ref***
  Yes 419 (1.9) 28 6.7 10.8 6.52 (2.56–16.63) 6.07 (2.48–14.81)
 Febrileb
  No 20,430 (93.8) 156 0.8 60.0 Ref Ref***
  Yes 1344 (6.2) 104 7.7 40.0 10.90 (4.60–25.85) 10.77 (7.93–14.62)
 Took antimalarial drugs in last 2 weeks
  No 21,742 (99.9) 253 1.2 97.3 Ref Ref***
  Yes 32 (0.1) 7 21.9 2.7 23.78 (9.52–59.41) 9.83 (3.35–28.81)
 >1 RDT-positive individual in household
  No 21,578 (99.1) 195 0.9 75.0 Ref Ref***
  Yes 196 (0.9) 65 33.2 25.0 54.41 (30.82–96.06) 26.57 (17.66–39.97)
 ≥1 individual in household spent ≥ 1 night away from home in the last month
  No 20,470 (94.0) 222 1.1 85.4 Ref Ref
  Yes 1304 (6.0) 38 2.9 14.6 2.74 (1.17–6.39) 0.94 (0.44–2.02)
CI confidence interval; IRS indoor residual spraying; OR odds ratio; Pf Plasmodium falciparum; Pv Plasmodium vivax; RDT rapid diagnostic test; Ref reference
* p < 0.05, ** p < 0.01, *** p < 0.001 from likelihood ratio test
a Slept under a mosquito net last night and/or household received IRS in the last 12 months
b Measured fever (axillary temperature ≥ 37.5 °C) or history of fever in last 24 h
c Adjusted Odds Ratios for all sociodemographic characteristics and malaria risk factors
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kebeles are not necessarily representative of Amhara 
Region or Ethiopia as a whole. Second, the effective cov-
erage was lower than desired, with an estimated 24.5  % 
of the targeted population not reached, which indicates 
that greater efforts would be needed to target the hard-
to-reach subgroups. Third, household enumeration was 
done for this study both prior to and during the interven-
tion. The household enumeration was not validated using 
satellite images or other means and it is possible that 
some households were enumerated more than once and 
that some households were never enumerated. Thus the 
coverage estimates should be interpreted with caution.
Conclusions
A population-wide malaria MTAT intervention is opera-
tionally feasible and can be conducted with high partici-
pation of those reached, although additional strategies to 
cover the hard-to-reach groups would be needed. RDT-
positivity is low and varies widely by kebele. Population 
movement is a driver of malaria transmission for older 
individuals (10 years of age and older) while intra-house-
hold transmission is a driver for individuals of all ages. 
This suggests the importance of strategies that target 
migrant workers and other travelers as well as strategies 
to improve mosquito net usage and IRS coverage. While 
several factors are significantly associated with a higher 
odds of RDT-positivity, many RDT-positive individuals 
do not have these risk factors. Parasite clearance strate-
gies that target populations for testing and treatment 
based on these risk factors alone are likely to leave many 
infections undetected.
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